Cytovance Secured $22.5M for Bio-Manufacturing Capabilities

The investment will enable Cytovance to expand its clinical trial and commercial scale cGMP manufacturing by funding facility, service and personnel expansion at its research and manufacturing operation.

Cytovance Biologics announced yesterday its secured financing of $22.5 million from Great Point Partners, LLC for the expansion of its biologic manufacturing capabilities in Oklahoma City.

The investment will enable Cytovance to expand its clinical trial and commercial scale cGMP manufacturing by funding facility, service and personnel expansion at its research and manufacturing operation in Oklahoma City. Cytovance will move to a nearby facility with laboratories recently vacated by Genzyme. Cytovance also acquired analytical and bioprocess equipment from Genzyme for the expanded facilities.

"Great Point reached out to us last year. It was evident from our first conversation they were very knowledgeable about the biol